Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152165 | 1.00 | HDAC1 (0.39) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| Methyl Alcohol SCHEMBL4653233 | 0.98 | HDAC1 (0.38) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL7713662 | 0.94 | HDAC1 (0.35) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL8060421 | 0.88 | ACHE (0.49) | ACHEBACE1FFAR1FFAR4GPR84 | |
| SCHEMBL943388 | 0.86 | FFAR1 (0.47) | ACHEBACE1FFAR1FFAR4GPR84 | |
| SCHEMBL1784404 | 0.84 | ACHE (0.36) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL1784402 | 0.84 | ACHE (0.36) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL7636971 | 0.84 | GPR84 (0.50) | FFAR1FFAR4GPR84LCKPPARD | |
| SCHEMBL7747945 | 0.84 | GPR84 (0.50) | FFAR1FFAR4GPR84LCKPPARD | |
| SCHEMBL3729898 | 0.84 | GPR84 (0.50) | FFAR1FFAR4GPR84LCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7591949-B2 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG (DE) | 2009-09-22 | — | — | US | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-7175850-B2 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-02-13 | — | — | US | claimed |
| US-20050123897-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG | 2005-06-09 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20030099694-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG (DE) | 2003-05-29 | — | — | US | claimed |
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1189598-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG (DE) | 2002-03-27 | — | — | EP | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2001001963-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG (DE) | 2001-01-11 | — | — | WO | claimed |
| WO-2001001962-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG. (DE) | 2001-01-11 | — | — | WO | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| US-20230390216-A1 | BROMHEXINE FOR THE TREATMENT OF PAIN | KERN KAI UWE (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-3638223-B1 | BROMHEXINE FOR THE TREATMENT OF PAIN | KERN KAI UWE (DE) | 2023-10-25 | — | — | EP | disclosed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001001963-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG (DE) | 2001-01-11 | — | — | WO | disclosed |
| WO-2001001962-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG. (DE) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | HDAC1 3833/4885HDAC2 4691/4885CHRM1 3222/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | HDAC1 3918/4885HDAC2 4744/4885CHRM1 3005/4885 |
| US-20030099694-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | ABCG2, NPC1L1, KIT | HDAC1 4123/4885HDAC2 3632/4885CHRM1 1705/4885 |
| US-20050123897-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | NPC1L1, ABCG2, SLC7A1 | HDAC1 4483/4885HDAC2 4075/4885CHRM1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.